

4/12/20

PROGRAMME OF LIVE SESSIONS: CET timing

The programme below will take place live. This time schedule corresponds to **CET timing**. [Click here](#) to adapt the CET time schedule to your own time zone.

If you want to ask questions during the Panel Discussions and Round Tables or if you want to test your knowledge and vote during Interactive Case presentations and debates, please make sure that you join us at the times indicated below.

Please also note that the Meet the Expert sessions and the Mentored Poster Walk will take place 100% live. To interact you must be online at the times indicated in the programme below.

Thank you for joining us. We wish you a good meeting



**E-Conference: 2nd How to Diagnose and Treat
CML / MPN**

February 25-28, 2021 – #CMLMPN2021

Chairs: Claire Harrison, Andreas Hochhaus, Ruben Mesa

Thursday, February 25th, 2021

13:55-14:00 Welcome

SESSION I – Optimizing cytoreduction

Chair: Jean-Jacques Kiladjian (Paris)

14:00-14:05	Introduction	Jean-Jacques Kiladjian (Paris)
14:05-14:15	Interactive case	Jean-Jacques Kiladjian (Paris)
14:15-14:35	Case-based lecture: Hydroxyurea / Resistance to Hydroxyurea	Alessandro Vannucchi (Florence)
14:35-14:55	Case-based lecture : Interferon	Heinz Gisslinger (Vienna)
14:55-15:15	Case-based lecture : Thrombosis	Brady L. Stein (Chicago)
15:15-15:25	Interactive case	TBA
15:25-15:30	<i>Brief oral communication</i>	TBA
15:30-16:00	<i>Panel discussion</i>	
16:00-16:10	Coffee Break	

4/12/20

SESSION II- Management of CML with TKI

Chair: François-Xavier Mahon (Bordeaux)

16:10-16:15	Introduction	François-Xavier Mahon (Bordeaux)
16:15-16:25	Interactive case	François-Xavier Mahon (Bordeaux)
16:25-16:45	Case-based lecture : First line TKIs	Giuseppe Saglio (Turin)
16:45-17:05	Case-based lecture: Use of generics	Tomasz Sacha (Krakow)
17:05-17:25	Case-based lecture: Salvage treatment and other lines	Gianantonio Rosti (Bologna)
17:25-17:35	Interactive case	TBA
17:35-17:40	<i>Brief oral communication</i>	TBA
17:40-18:10	<i>Panel discussion</i>	
18:20-19:20	<i>Mentored poster walks</i>	

Friday, February 26th, 2021

13:00-14:00 Slot for a possible Symposium (already booked)

SESSION III – MPN risk stratification including vascular events

Chair: Francesco Passamonti (Pavia)

14:10-14:15	Introduction	Francesco Passamonti (Pavia)
14:15-14:25	Interactive case	Francesco Passamonti (Pavia)
14:25-14:45	Case-based Lecture: Essential Thrombocythemia	Alberto Alvarez (Barcelona)
14:45-15:05	Case-based lecture : Polycythemia Vera	Naseema Gangat (Rochester)
15:05-15:25	Case-based lecture: Pre-Myelofibrosis & Myelofibrosis	Paola Guglielmelli (Florence)
15:25-15:35	Interactive case	TBA
15:35-15:40	<i>Brief oral communication</i>	TBA
15:40-16:10	<i>Panel discussion</i>	
16:10-16:20	<i>Coffee break</i>	
16:20-17:15	DEBATE 1 – Interferon alpha should be front line therapy in all ET/PV patients	
	Chair: Ruben Mesa (San Antonio)	
16:20-16:25	Introduction	Ruben Mesa (San Antonio)
	<i>Audience votes YES or NO</i>	

4/12/20

16:25-16:40 Yes Florian Heidel (Greifswald)

16:40-16:55 No Claire Harrison (London)

16:55-17:15 *Discussion*

Audience votes again YES or NO

17:15-18:25 ROUNDTABLE 1 – Infections in myeloproliferative disorders, including CML
Chair: Ruben Mesa (San Antonio)

17:15-17:20 Introduction Ruben Mesa (San Antonio)

17:20-17:35 COVID-19 and CML Delphine Réa (Paris)

17:35-17:50 COVID in MPN Tiziano Barbui (Bergamo)

17:50-18:05 Infections in MPN - patients survey Florian Heidel (Greifswald)

18:05-18:25 *Discussion*

18:35-19:35 3 Simultaneous Meet the Expert sessions

Saturday, February 27th, 2021

09:00-10:00 Slot for a possible symposium (already booked)

10:00-10:10 Coffee Break and Poster viewing

10:10-11:15 ROUNDTABLE 2 – Pregnancy and parenting
Chair: Jane Apperley (London)

10:10-10:15 Introduction Jane Apperley (London)

10:15-10:30 Pregnancy and TKI Elisabetta Abruzzese (Rome)

10:30-10:45 Russian recommendations to manage pregnancy in CML Ekaterina Chelysheva (Moscow)

10:45-11:00 Interferon alpha in pregnancy Martin Griesshammer (Minden)

11:00-11:20 *Discussion*

11:20-12:15 DEBATE 2 – Allogeneic stem cell transplantation should be considered third line option in chronic phase CML
Chair: Andreas Hochhaus (Jena)

11:20-11:25 Introduction Andreas Hochhaus (Jena)

Audience votes YES or NO

11:25-11:40 Yes Jane Apperley (London)

4/12/20

11:40-11:55 No Delphine Réa (Paris)

11:55-12:15 *Discussion*

Audience votes again YES or NO

12:15-13:55 Lunch

12:45-13:45 Slot for a possible symposium (already booked)

SESSION IV – Evolving therapies in Myelofibrosis

Chair: Ruben Mesa (San Antonio)

13:55-14:00 Introduction Ruben Mesa (San Antonio)

14:00-14:10 Interactive case: Ruben Mesa (San Antonio)
(incl. approved JAK inhibitors - Ruxoitinib, Fedratinib)

14:10-14:30 Case-based lecture: Other JAK inhibitors Adam Mead (Oxford)
(Momelotinib, Pacritinib)

14:30-14:50 Case-based lecture: JAK inhibitors in combination Srdan Verstovsek (Houston)

14:50-15:10 Case-based lecture: Other agents John Mascarenhas (New York)

15:10-15:20 Interactive case TBA

15:20-15:25 *Brief oral communication* TBA

15:25-15:55 Panel discussion

SESSION V – Management of advanced disease (MPN and CML)

Chair: Claire Harrison (London)

15:55-16:00 Introduction Claire Harrison (London)

16:00-16:10 Interactive case Claire Harrison (London)

16:10-16:30 Case-based lecture: Transplantation in Myelofibrosis & CML Nicolaus Kröger (Hamburg)
in advanced phase

16:30-16:50 Case-based lecture: Myelofibrosis transforming to AML Vikas Gupta (Toronto)
(agents & approaches)

16:50-17:10 Case-based lecture: Blast crisis in CML Dragana Milojkovic (London)

17:10-17:20 Interactive case TBA

17:20-17:25 *Brief oral communication* TBA

17:25-17:55 Panel discussion

18:05-19:05 3 Simultaneous Meet the Expert Sessions

Sunday, February 28th, 2021

SESSION VI – Treatment free remission in CML

Chair: Susanne Saussele (Mannheim)

09:25-09:30	Introduction	Susanne Saussele (Mannheim)
09:30-09:40	Interactive case: Prognostic factors for successful TFR	Susanne Saussele (Mannheim)
09:40-10:00	Case-based lecture: New technologies in monitoring	Nick Cross (Southampton)
10:00-10:20	Case-based lecture: New treatments for stem cell eradication	Thomas Ernst (Jena)
10:20-10:40	Case-based lecture: Interferon alpha	Andreas Burchert (Marburg)
10:40-10:50	Interactive case	TBA
10:50-10:55	<i>Brief oral communication</i>	TBA
10:55-11:25	<i>Panel discussion</i>	
11:25-12:10	Keynote lecture	
	Chair: Claire Harrison (London)	
11:25-11:30	Introduction	Claire Harrison (London)
11:30-11:50	TBA	TBA
11:50-12:00	Discussion	
12:00-12:05	<i>Closing remarks</i>	

MEETING CLOSURE